Background: The pathogenesis of Alzheimer's disease is attributed to misfolding of Amyloid-b (Ab) peptides. Ab is generated during amyloidogenic processing of Ab-precursor protein (APP 
Introduction
The most common form of dementia in the world is Alzheimer's disease (AD), affecting about 1% of the human population by aged 65, and rising to 35-40% after age 85. Evidence points to a key role for misfolded amyloidogenic Ab peptides in the pathogenesis of AD (amyloid cascade hypothesis). The accumulation of Ab as plaques in the hippocampus and other brain regions is a key characteristic of AD pathology [1, 2] .
Ab peptides are generated during amyloidogenic processing of Ab-precursor protein (APP). When APP is cleaved by b-secretase, the soluble ectodomain (sAPPb) is released extracellularly whilst the 99 amino acid C-terminal fragment (C99) remains membrane bound. In a second proteolytic event, C99 is cleaved by the csecretase. Two peptides are released, Ab peptide consisting of either 40 or 42 amino acids (Ab40 and Ab42, respectively) and an intracellular product (AID or AICD), which regulates apoptosis [3] and transcription [4] . An alternative, non-amyloidogenic pathway also exists. In this pathway APP is cleaved by a-secretase in the Ab sequence producing the soluble ectodomain (sAPPa) and the membrane bound 83 amino acid C-terminal fragment (C83). C83 is also further cleaved by the c-secretase into the P3 and AID peptides.
The degree to which APP function plays a role in the pathogenesis of AD is unclear but changes in the apoptotic and axonal activities of APP may underlie some aspects of AD pathology [5, 6] . However, until the in vivo functions of APP are better understood this will remain a crucial question. APP null mice have retarded neuron development, reduced hippocampal neuron viability, diminished grip strength, locomotor activity and postnatal growth [7] , but can be normalized by over expression of the sAPP-a ectodomain [8] . However, since the essential functions of APP are compensated for by homologues APLP1 and APLP2, the physiological significance of the short intracellular C-terminal domain remains relatively unexplored in vivo.
The ,50 amino acids long APP intracellular region contains seven residues that can be phosphorylated andseveral of these amino acids are hyperphosphorylated in human AD brain. However,it remains unclear whether this is a cause or a consequence of neurodegeneration. One of these sites of particular functional significance is Tyr 682 , the phosphorylation of which is increased in AD patients [9] , especially in vasculature tissue of the brain [10] . This residue forms an essential part of the evolutionarily conserved, canonical endocytic Y 682 ENPTY 687 motif. Compromised endocytosis of APP is shown to significantly decrease amyloidogenic processing and Ab secretion [11] . This motif is also a docking site for cytosolic proteins, such as Fe65, that regulate APP metabolism and signaling [12] . Phosphorylation of Tyr 682 promotes interaction of Src-Homology 2 domain (SH2) while it reduces interaction with a subset of proteins containing a Phospho-Tyrosine-Binding (PTB) domain in vitro [13, 14] . The potential role of Tyr 682 phosphorylation state as a ''biochemical switch'' to change the molecular composition of APP complexes is an intriguing possibility. In the AD brain, a possible pathological role for augmented APP phosphorylation on Tyr 682 needs further exploration. To begin to specifically dissect the functional role of APP intracellular domain in vivo we have generated APP KI mice with a mutation in amino acid Tyr 682 . Here we describe the generation and initial characterization of APP KI mouse with mutation of Tyr 682 mutation of Tyr 682 .
Materials and Methods

Ethics Statement
Mice were handled according to the Ethical Guidelines for Treatment of Laboratory Animals of Albert Einstein College of Medicine. The procedures were described and approved in animal protocol number 20040707
Generation of APP Y682G and T668A mutant Mice A 7.0-Kb genomic fragment containing exon 16 from C57BL/6 BAC DNA (RP23-99P18) was amplified by PCR with the following primers:
Fwd: 59-aaaaGGTACCagtatctcttgtcctcacaatg-39; Rev: 59-aaaaCCGCGGtaggtcccaaggcta-39. This fragment flanked by KpnI and SacII sites was cloned into pBS (pBS-EX16), and used as a template for subsequent cloning. Two nucleotide mutations were introduced into pBS-EX16 vector by site directed mutagenesis PCR. Firstly a SmaI/XmaI restriction site (CCC GGA R CCC GGG) was created right in front of exon 16 by using the following primers:
Fwd: 59-ctattttaaacccggatctctgtacctgctttc-39; Rev: 59-gaaagcaggtacagagatccgggtttaaaatag-39. This new restriction site was used to verify the targeted clone. Furthermore the nucleotide change from either ACC to GCC or TAT to GGA in exon 16 generated the corresponding amino acid mutation T668A or Y682G, respectively. The following primers were used for this mutation: for T66A mutation, Homologous recombinants were selected with G418 (200 mg/ ml) and dTA exclusion. Injection of the two Y682G mutant targeted ES cell clones into C57BL/6J blastocysts was performed at the Albert Einstein College of Medicine gene-targeting facility, according to the facility protocol.
PCR Analysis
The PCR screening was performed using the Expand Long Template PCR System (Roche-applied-Science) with Betaine, according to the manufacturer instructions. PCR analysis of recombinant ES cells and mice was conducted with the following primers and digestion strategies to identify the correct recombinant clones and strains:
ES 
Southern Blot Analysis
Twenty mg of genomic DNA was digested with BamHI overnight, run on a 1% TAE agarose gel and transferred on a Hybond-N+ membrane (Amersham).
The probe was prepared by PCR from a BAC clone (RP23-99P18) with the following primers:
-Left arm: One mg of PCR probe was labelled with 5 mL of 32P-dCTP (3000 Ci/mmol, ICN) and purified through a Push Column (Stratagene) according to the manufacturer's protocol. Membranes, containing the cleaved genomic DNA, were hybridized at 65uC and subsequently washed 4 times in SSC buffer (Sigma). Film was exposed to the hybridised membranes at 280uC and then developed.
Immunoblot analysis
Whole mouse brain was dounce homogenized (1:10 w/v) in tissue homogenization buffer (20 mM Tris-base pH 7.4, 250 mM sucrose, 1 mM EDTA, 1 mM EGTA plus protease (Roche, Complete) and phosphatase inhibitors. For detection of full length APP or APP CTF's, the lysates were spun at 1,000 g for 15 min and an equal amount whole protein homogenates were loaded for either 4-20% SDS-PAGE or 13% tris-tricine SDS-PAGE respectively and transferred onto nitrocellulose membranes for detection using AbD (Zymed). For detection of sAPPa and b (IBL antibody #27724 & #27722, respectively) an additional 45 min spin at 100,000 g was used to remove membranes prior to SDS-PAGE. Finally, in order enhance the signal for detection of both sAPPb and APP CTF's, the nitrocellulose membranes were subject to epitope retrieval, prior to blocking, through incubation with boiling PBS-T and subsequent cooling to room temperature.
Reverse Transcriptase-PCR and Real Time Quantitative PCR Analysis Mouse brain mRNA was extracted with Trizol reagent (Invitrogen). Briefly, one mouse hemisphere was shock frozen, weighed and homogenized in 4 volumes of Trizol reagent with an electric dounce homogenizer, 3630'' in ice. The suspension was cleared of debris and membranes by centrifugation, and nucleic acids were separated by chloroform extraction and ethanol precipitation. The mix was applied to RNeasy columns, and RNA purified with RNeasy Protect Kit (Qiagen) according to the manufacturers' protocols, including on-column DNase digestion (Qiagen). One mg of RNA, quantified with the Nanodrop (Thermo Scientific), was reverse-transcribed to cDNA using random primers and the SuperScript III First-Strand Synthesis System for RT-PCR kit (Invitrogen). Real time PCR was based on the TaqMan technology, using 200 ng of cDNA and mouse APP, Beta Actin and beta-2-microglobulin inventoried assays (Mm01344172_m1, Mm00607939_s1 and m00437762_m1, Applied Biosystems) according to the manufacturer's protocols, in 20 mL volume and in 96well plate format. The threshold cycles (Ct) for the endogenous controls mRNA (b-actin and b-2-microglobulin) and the target (APP) signal were determined and the relative RNA quantification was calculated using the comparative DDCt method. Each experiment was conducted in triplicate. Data analysis was conducted according to Applied Biosystems references and protocols, and using student-t test.
Neuronal cultures
Neuronal cultures were performed as described previously [15, 16] from E16-17 fetuses.
Mouse Dermal Fibroblasts
To culture mouse dermal fibroblasts (MDFs), skin was removed from mouse tails, soaked in 70% ethanol, washed in PBS, diced into small pieces and incubated at 37uC overnight in CO 2 incubator in DMEM containing 20% FBS, supplemented with penicillin/streptomycin and 1.6 mg/ml collagenase II. On the next day, clumps were removed by passing through a nylon mesh, and the material was centrifuged at 1000 rpm for 5 min to collect the cells. The collected cells were maintained in DMEM containing 20% FBS and penicillin/streptomycin.
Biotinylation and streptavidin precipitation
For biotinylation experiments, MDFs were washed three times with cold PBS plus Ca ++ and Mg ++ (PBS-CM) and labelled for 30 min on ice in 0.5 mg/ml sulfo-NHS-SS-biotin (Pierce) dissolved in PBS-CM. Free biotinylation reagent was removed by washing three times with PBS-CM containing 0.1% BSA. The cells were lysed in the RIPA buffer. The lysates were cleared by centrifuging at 20,000 g for 10 min, and were mixed with streptavidin agarose beads (Sigma S1638). After collecting unbound lysate, the beads were washed four times with the RIPA buffer, and were boiled in 26 SDS buffer. Comparable volume of the samples were subjected to western blot.
Synaptosomes
For synaptosomes, mouse brain was homogenized in H buffer [5 mM Hepes/NaOH pH 7.4, 1 mM EDTA, 1 mM EGTA, 0.32 M sucrose, plus protease (PI) and phosphatase (PhI) inhibitors] at 10% (w/v) and centrifuged at 800 g for 10 min. The supernatant (S1) was separated to supernatant (S2) and pellet (P2) by spinning at 9,200 g for 15 min. P2 was lysed on ice for 30 min in H buffer containing 35.6 mM sucrose. The lysed P2 was separated to supernatant (LS1) and pellet (LP1) by spinning at 25,000 g for 20 min. S2 was separated to supernatants (S3) and pellet (P3) by spinning at 165,000 g for 2 hrs, respectively. P3 was suspended in H buffer containing 0.32 M sucrose by sonication. Synaptosomes fractions represent: S1, postnuclear supernatant; S2, cytosol, soluble proteins and light membrane; P2, crude synaptosomal fraction; S3, soluble fraction; P3, light membrane abundant in Golgi and ER; LS1, crude synaptic soluble; LP1, synaptic membrane fraction.
Ab40 ELISA
DEA extraction of Ab from brain lysates was carried out as previously described [17] . Prior to ELISA, DEA extracts were further purified with Oasis HLB sample extraction cartridges (Waters, WAT094226) to decrease background artifacts which otherwise prevent detection of endogenous wild-type Ab40 in mice [18] . Ab40 ELISA kit (IBL America, discontinued product) was used according to manufacturer's protocol with equal quantities of protein loaded.
Co-immunoprecipitation
Whole mouse brain lysate was centrifuged at 9000 g for 15 min and the resulting supernatant at 100,000 g for 45 min. The supernatant was removed and the membrane pellet re-suspended overnight in IP buffer (20 mM Hepes pH 8.0, 10% glycerol, 137 mM NaCl, 0.5% Triton-X-100, 2 mM EDTA) Any remaining debris was removed with centrifugation at 9000 g for 15 min and the membrane enriched supernatant diluted to 1 mg/ml in IP buffer. 500 ug of membrane protein was used for each IP. Supernatants were pre-cleared with 30 ul protein A/G (Pierce) for 30 min. 2 mg of either monoclonal anti-APP, non-specific mouse monoclonal control, anti-Fe65 (I12) [19] or non-specific rabbit polyclonal control were added for incubation for 30 min. 20 ul protein A/G was then added for overnight incubation. Supernatant was removed and the beads were washed 46 with IP buffer. Beads were re-suspended in 16 LDS buffer with 10% BME and 1% NEM and incubated for 5 min at 95uC. Immunoblot analysis was carried out as described above with a-APP IP probed for Fe65 and a-Fe65 IP probed for full length APP (22C11 antibody, Millipore, 1:1500).
Pathological evaluation
Complete necropsy was performed on all mice and tissues collected were fixed in Tellyesniczky/Fekete fixative (100 ml 70% ethanol, 5 ml 37-40% formalin, 5 ml glacial acetic acid). Appropriate tissues were decalcified using 10% formic acid (Formical-2000H, Decal Chemical Corporation, Tallman, NY) or 3% hydrochloric acid (Cal-ExH, Fisher Scientific, Fairlawn, NJ) for 24 hours. Tissues were paraffin embedded and stained with hematoxylin and eosin (H&E). A board certified veterinary pathologist with no knowledge of the genotypes analyzed the slides.
Results
Generation of APP Y682G and T668A Mutant Mice
The targeting strategy for the generation of the APP KI mice entailed the replacement of APP exon 16 with exon 16 carrying the Y682G or T668A mutation (Fig. 1A) . The vector used the floxed PGK-neo selection cassette and contains a 59 homologous region and the negative selection cassette, PGK-dta. The 39 homologous region introduced the T668A or Y682G mutation, BamHI and SmaI sites into the APP mouse gene. The linearized targeting vector was transfected into 129 ES cells. In the presence of the positive selection drug, G418, clones only survived if both the PGK-neo selection cassette was integrated and the PGK-dta cassette was removed by homologous recombination. ES cell clones carrying the targeting vector by random, non-homologous integration, were eliminated due to expression of diphtheria toxin.
After selection, ES cell clones carrying the proper homologous recombination and the Y682G or T668A mutant allele were identified by PCR for 39 region (i.e. right Arm: if homologous recombination had occurred these primers would amplify a product of 3.2 Kb). Out of ,600 screened ES clones, we found two targeted clones for T668A and four clones for Y682G mutation (Fig. 1B) . Also, PCR amplification and digestion was used to check the proper insertion of the construct in the genomic DNA and the removal of the Neo cassette (not shown).
The occurrence of homologous recombination was confirmed by both sequencing and Southern blot analysis (Fig. 1C) . DNA derived from individual Y682G or T668A ES clones was digested with BamHI, gel separated, blotted into a nylon membrane and hybridized with the 39probe. The 39 probe hybridizes with a ,7.5 Kb fragment derived from the wild-type locus. Homologous recombination at the 39 homologous region yields a ,6.0 Kb fragment upon BamHI digestion due to the introduction of the BamHI site and the PGK-neo selection cassette. ES clones (T668A or Y682G) carry a wild type allele (7.5 Kb) and a recombined allele (6.0 Kb). The 7.5 Kb and 6.0 Kb bands had a similar intensityproving the ES cells selected were clonal populations. Similar results were obtained when homologous recombination at the 59 site was assessed.
Two ES cell clones each for Y682G or T668A (129, agouti coat color), carrying the correct site-specific homologous recombination, were injected into C57BL/6J blastocysts (black coat color).
The resulting chimeras with a high proportion of agouti coat color (i.e. with a high relative contribution from the injected ES cells) were backcrossed to C57BL/6J mice to obtain heterozygous Y682G/wt, which were identified by PCR and Southern analysis as described above (not shown) using tail DNA. Heterozygous mice were crossed to Meu40-Cre mice to obtain Meu40/APP Y682G/wt or Meu40/APP T668A/wt animals. Cre is a bacteriophage P1-encoded recombinase that catalyzes site-specific recombination between two 34 bp loxP recognition sites, resulting in the excision of the intervening DNA sequences. The resulting mice are named APP Y682G or APP T668A and are abbreviated to APP YG or TA respectively, where appropriate.
Reduced b-cleavage and enhanced a-processing of APP Y682G mutant mice Previous studies have shown an important role for Tyr 682 in shifting APP toward the amyloidogenic (b-processing) rather than the non-amyloidogenic (a-processing) pathway in vitro [11] . Using the models described above we established whether this is true in vivo. Rates of a and b processing are reflected by the relative abundance of the products of these two pathways, sAPP-a and sAPP-b, respectively. Using immunoblot analysis an approximately 15-fold increase in sAPP-a in conjunction with a 3.5 fold decrease in sAPP-b was detected in brain tissue from APP YG/YG mice compared to APP wt/wt controls ( Fig. 2A & 2B) . Importantly, no differences in sAPP-a and sAPP-b between APP TA/TA , APP TA/ wt and APP wt/wt mice (Fig. 2C ) was detected thus demonstrating the highly specific role of Tyr 682 in modulating entry of APP into the amyloidogenic pathway in vivo.
An analysis of APP COOH-terminal fragments (Fig. 2D) shows that C83, which is formed in conjunction with sAPP-a, is greatly increased in APP YG/YG mice over APP wt/wt control, consistent with an increase in non-amyloidogenic processing. The level of C99, which is formed in conjunction with sAPP-b, does not change appreciably. Interestingly, the level of the phosphorylated APP COOH-terminal fragments, p-C99, p-C89 and p-C83, were unchanged in APP YG/YG but, consistent with observations by Sano, Y. et al. [20] , were below detectable levels in APP TA/TA mice. This indicates that the steady-state phosphorylation of APP is predominantly located on Thr 668 in the brain and that phosphorylation of Tyr 682 is highly regulated (perhaps by signaling mechanisms) and may have a short half-life. Also, it shows that the Y to G mutation has not grossly altered the structure of the APP intracellular domain that since the mutant APPYG protein still undergoes other phosphorylation events. Other products of the amyloidogenic pathway are Ab40 & 42. Only Ab40 was detectable and showed a significant 25% decrease in APP YG/YG mice compared to APP wt/wt controls (Fig. 2E) , which was also consistent with a decreased b-processing of APP. The change was specific for the Y682G mutation since Ab40 levels were not changed in the APP TA/TA mice, again in agreement with previous findings [20] . Total APP levels show a 64% increase in APP YG/YG over controls, after normalization with Tubulin ( Fig. 2A & B) . Whether this indicates an increased total half-life of APP Y682G as compared to WT APP remains to be determined. It is also possible that manipulation of the APP gene locus may have altered the transcription/splicing of the mutant allele. To test for this, we have now performed real-time RT-PCR and the data demonstrate that expression levels of APP mRNA are not affected by the genetic strategy used to do the KI (Fig. 3A) . Thus any alterations in APP protein and in its metabolites almost certainly reflect an effect of the YG mutation on the fate of the APP protein, since it is very unlikely that the point mutation will affect the translational efficiency of the KI mRNA. Moreover, this increase in total APP is not always reproducible (APP levels are similar between the two strains in the experiments shown in Fig 2C, Fig. 4 and Fig. 5 ). The reason for this variability is not presently understood.
Since a-and b-cleavages are mutually exclusive, an increase in one should be compensated by roughly equal decrease in the other if all full length APP is cleaved, in similar proportions, by either aor b-secretase. However, we report a ,15-fold increase in soluble sAPP-a but only a ,3.5 -fold decrease in sAPP-b. Unless in vivo sAPP-b is cleared more efficiently than sAPP-a, these differences are not consistent with the aforementioned model. A recent report shows that APP is cleaved in the ectodomain buy an alternative, albeit yet to be identified, protease [21] . In addition, a large fraction of full length APP is processed by lysosomes, presumably after APP is internalized [22] (Fig. 3B) . The YG mutation could reduce BACE and lysosomal degradation of APP, if mutant APP has impaired endocytosis [both processes are largely dependent of APP endocytosis [22, 23, 24] ). This would also explain the vast increase in a-secretase processing of the YG APP mutant. This hypothesis is presently being investigated.
Also C83 and C99 undergo lysosomal degradation (Fig. 3B ), indicating that these APP metabolites are not exclusively cleaved by g-secretase. Interestingly, inhibition of lysosomal degradation results in the appearance of several COOH-terminal APP fragments larger than C99 [see asterisks in Fig. 3B for both primary neurons and primary mouse dermal fibroblasts (MDFs)]. These fragments are either intermediated of APP degradation in lysosomes, or are produced by processing of APP in regions NH 2 -terminal to the BACE1 cutting site, suggesting that the APP ectodomain can be processed by several unknown proteases, in addition to a-and b-secretase.
The decrease in Ab40 level (25%) is not as pronounced as the reduction in sAPPb levels. This apparent discrepancy can be explained by either reduced clearance of brain Ab, a compensatory increase in c-cleavage of C99, or by reduced clearance of C99 by the lysosomes. These possibilities are being investigated.
As noted above, intracellular transport and localization of APP are critical components of APP processing and Ab production. In fact, a-secretase cleaves mAPP en route to or on the plasma membrane. b-secretase predominantly cleaves mAPP in early endosomes [23, 24] while C99 and C83 are processed by the csecretase in endocytic compartments [24] . Thus, the shift toward the non-amyloidogenic processing in APP YG/YG mice may involve a role of Tyr 682 in trafficking of APP along the secretory pathway. However, the YG mutation neither altered the imAPP/mAPP ratio in brains (Fig. 4A and B) and primary mouse dermal fibroblasts (MDFs) (Fig. 4C) , nor changed the levels of plasma membrane mAPP in MDFs (Fig. 3C) .
Normal brain organization and distributions of neural proteins in APP YG/YG mice
A number of studies suggest important neurological roles for APP and APP polypeptides derived by secretases processing. sAPP-a is neuro-protective [25, 26, 27, 28] . A metabolite of sAPP-b interacts with DR6 to trigger neuronal death [29] . Ab is critical for LTP induction and memory acquisition [30] . AID/AICD modulates cell death, gene transcription and Ca ++ homeostasis [3, 4, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40] . Because APP derived polypeptides are significantly changed in APP YG/YG mice, we analyzed whether these mutant mice show abnormalities in brain organization. First, a general histopathological examination of the APP YG/YG mouse showed the following. All mice had minimal multifocal myofiber degeneration affecting the appendicular musculature, primarily, the biceps femoris, quadriceps, and triceps brachii muscles. Randomly scattered throughout the striated muscles were small clusters of swollen muscle fibers with increased cytoplasmic eosinophilia and occasional karyorrhexis ( Figure 5 ). These myofibers were surrounded by myocytes with variable cross sectional diameter and occasional rowing of central nuclei interpreted as myofiber regeneration. Coronal step sections of the brain were made at the five following levels-olfactory bulbs, cerebral cortex, thalamus, midbrain and medulla. Each of these regions was further serially sectioned at 250-micron intervals and stained with H&E. Histological examination revealed no structural or anatomical differences between the APP YG/YG and the wild type mice (Fig. 6 ). Next, we tested distribution of neural proteins using a biochemical approach. Recent evidence suggest a role for APP in synaptic function and numerous data support a role for synaptic dysfunction underlying subtle memory changes in AD [41] . Since the presynaptic regions of neurons are thought to be the main source of Ab in the brain, attention has been focused on axonal APP trafficking. These studies have unveiled an active role for APP in axonal transport. APP is transported anterogradely by conventional kinesin in tubular vesicles [42, 43, 44, 45, 46, 47, 48] . Although a direct interaction of APP with the motor protein kinesin-1 has been proposed [49] , following studies have contradicted this conclusion [50, 51] and shown that APP interacts with kinesin-1 trough the APP-interacting proteins JIP1, a c-Jun N-terminal kinase JNK-signaling scaffold protein [51, 52, 53] . It has also been proposed that b-(BACE1) and c-secretases transported in APP-containing vesicles and that APP functions as a receptor for the cargo transport [54] . A number of observations suggest that microtubule-dependent axonal transport is impaired in AD human brains [5, 55, 56, 57, 58] as well as APP transgenic mice [5, 59, 60] . Because of the indication that the intracellular domain of APP is important for axonal transport of APP and cargo molecules, we analyzed the synaptic distribution of neural proteins. We studied APP. BACE1, a component of the csecretase complex, Nicastrin, and synaptic proteins/receptors, such as PSD95, SVP38, the Glutamate receptors NMDAR1, NMDAR2A, NMDAR2B and GLuR2/3/4. The synaptic levels of these proteins were unchanged (Fig. 7) , further supporting the notion that the YG mutation does not affect APP maturation and trafficking and that APP may not be a regulator of fast anterograde axonal transport.
Absence of APP/Fe65 interaction in APP Y682G mutant mice
Several cytosolic proteins bind APP. These APP-interacting proteins regulate both APP processing and functions of APP polypeptides in vitro [51, 52, 53, 61, 62, 63, 64, 65, 66, 67, 68] . However, the in vivo relevance of these findings is still unclear. Most of these interactions involve the YENPTY sequence (amino acids 682-687) of APP. Phosphorylation of APP is consequential. Some proteins interact with APP only when Tyr 682 is phosphorylated [14, 69, 70, 71] ; others, like Fe65, Fe65L1 and Fe65L2, only when this tyrosine is not phosphorylated [13] . The same is true for Thr 668 [67, 72] . These data suggest that phosphorylation-dephosphorylation on Tyr 682 and Thr 668 modulates APP interactions and function. Notably, Tyr 682 and Thr 668 phosphorylation is increased in AD brains [9, 73] . The APP/Fe65 interaction is the best characterized of many potential APP/APP C-terminal binding protein complexes. In vitro studies have suggested a role for APP/ Fe65 complexes in APP metabolism, and for AID-AICD/Fe65 in gene transcription [4, 62, 74] . Tyr 682 is essential for a robust APP/ Fe65 interaction to occur in vitro [75] 
Discussion
Mis-folding of amyloidogenic Ab peptides, particularly Ab42, is a key feature of the AD pathology. APP Y682G mutation in mice clearly results in a large redistribution of APP towards nonamyloidogenic pathway; sAPP-a and C83 are greatly increased while sAPP-b and Ab40 are decreased (Fig. 2) , thus demonstrating the necessary role of the C-terminal in normal activity of the amyloidogenic pathway in the brain and consistent with the results observed in vitro. It is not yet apparent why a concurrent reduction in C99 or p-C99 was not observed. It is interesting to speculate, based upon previous findings, how this profound shift in APP processing may influence physiology in APP YG/YG mice. sAPP-a for instance is a proposed growth factor with neuroprotective properties, therefore the 15-fold over expression may result in different growth characteristics and a resistance to stress, although no differences in brain organization were apparent in our analysis (Fig. 5, 6) .
A possible mechanism to explain this shift toward the nonamyloidogenic processing may involve the essential role of Tyr 682 for normal endocytosis of APP as previously shown in vitro [11] . A fraction of APP is cleaved by a-secretase in a post-Golgi compartment or at the plasma membrane. Alternatively, some APP is processed by b-secretase in the Golgi or in late endosomes following internalization from the cell membrane. In addition Ab levels tightly correlate with APP internalization such that Ab secretion is significantly decreased when APP endocytosis is compromised in vitro [23, 24] . However our initial analysis of APP localization shows no difference in cell surface APP (Fig. 4C ).
We also demonstrate that Tyr 682 is necessary for interaction between APP and binding partner Fe65 in vivo (Fig. 8) . Interestingly Fe65 also plays role in endocytosis of APP. Fe65 simultaneously binds to the cytoplasmic tail of APP and of LRP1 into a trimeric complex [62, 76, 77] . This interaction results in accelerated endocytosis of APP via clathrin-coated pits and in delivery to late endosomal compartments for cleavage by b-and csecretase to generate Ab [72] . The decrease in amyloidogenic processing in APP YG/YG mice may be consistent with this data. Another known function of the APP/Fe65 interaction, which should be absent in APP YG/YG mice, is the transcriptional activity of AID/Fe65/Tip60 complex [4] , although further investigation will be needed to determine if this is true. Also of note is that phosphorylation of Tyr 682 also disrupts interaction of APP with Fe65 and other PTB domain proteins [13, 14] (Fig. 2D) . Counter intuitively, this observation may exemplify the importance of Tyr 682 phosphorylation. Evidence shows Tyr 682 is hyperphosphorylated in the AD Brain [9, 10] . It is plausible that excessive phosphorylation at this functionally important residue could lead to toxic effects, given its relative scarcity under normal conditions. For example, if Tyr 682 phosphorylation plays a role in targeting APP for degradation via secretase, lysosomal or mice phenotype reproduced in a context that allows a much more detailed picture of APP function to be dissected. Physiological characterization of this model in addition to APP YG/YG mice is therefore of great interest.
In summary, we have successfully generated two APP KI mouse lines, APP Y682G & T668A, and carried out an initial characterization focusing on APP Y682G. Both APP processing and the APP/Fe65 interaction are significantly altered as a result of this mutation, in agreement with previous in vitro studies. In addition these findings have a therapeutic implication, demonstrating that manipulation of this amino acid could increase production of the sAPPa, considered a protective protein, and decrease the generation of toxic fragments such as Ab40 & 42. without negative physiological consequences. Overall, the data suggests a very important in vivo role for Tyr 682 in the brain.
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